Click it and Unblock the Notifications
Latest Updates
-
The Protein Gap In Women’s Diets: Gynaecologist Explains Why This Nutrient Matters From Puberty To Menopause -
Ralph Lauren Showcases ‘Jhumkas’ At Paris Fashion Week, Rekindling Debate On Credit For Indian Craft -
Viral Video: Pakistani Family Celebrates India’s T20 World Cup Victory With Cake, Sings Indian National Anthem -
Who Is Aditi Hundia? Viral Video Shows Ishan Kishan Celebrating India’s T20 World Cup Win With Girlfriend -
India Seal Historic T20 World Cup Win: Samson Tournament Star, Bumrah Match Hero, Dhoni Posts Special Message -
Horoscope for Today March 09, 2026 - Small Steps, Big Progress -
International Women’s Day 2026: 7 Powerful Ayurvedic Foods Every Woman Should Start Adding To Her Daily Diet -
What If WiFi, GPS Or Dishwashers Didn’t Exist? This Instagram Reel Credits Women Behind Everyday Inventions -
Women’s Day 2026: Why Creating Relaxation Spaces At Home Matters For Women Balancing Multiple Roles -
Women’s Day 2026 Binge Watch: 10 Movies That Celebrate Women Who Challenge Norms And Rewrite Their Stories
Drug For Anemic Cancer May Raise Death Risk!
The FDA approved drugs, called to boost their and health, can do so by possibly stimulating the growth of cancer cells.
The finding came to light after a meta-analysis of 51 trials involving a total of 13,613 patients.
The research team found that cancer patients who took ESAs had a 10 percent increased risk of death as compared to those patients who kept away from the drugs.
"The FDA says if you use the drug in moderation, it should be safe. But our findings, in conjunction with basic science studies, raise the concern that the drug may be stimulating cancer and shortening cancer patients' survival," said Charles Bennett, M.D., the lead author of the study.
It's troubling that 15 years after the drug came out, we finally came to this realization.
"It's troubling that 15 years after the drug came out, we finally came to this realization.
"The current FDA recommendation is these drugs are safe for cancer patients as long their hemoglobin levels aren't raised too high. Our data do not support that," he added.
Dr Stephen Lai, one of the study's co-authors who tested the response of cancer cells to an ESA called erythropoietin in the laboratory, said that the tests had shown that the dugs had a significant effect.
"We saw a dramatic change. Adding 'epo' (erythropoietin) to the cells increased their ability to migrate or invade. Our basic science findings and the clinical trial results suggest that giving cancer patients 'epo' for their anemia may actually cause their tumors to progress," he said.
The study also confirmed a previously known 57 percent increased risk of in the legs or lungs for cancer patients receiving ESAs.
Lai cautioned that various solid tumors such as breast cancer, colon cancer and melanoma may react differently to ESAs.
"The exact effect and size of that effect may be different depending upon the type of tumor. Additional research is clearly necessary, and we have to be careful about generalizing these results before further research is conducted," he said.
The study and its findings will be published in the Journal of the American Medical Association Wednesday, February 27.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.
Continue with Google